Beyond expectations: safinamide’s unprecedented neuroprotective impact on acute spinal cord injury

Basit Öğe Kaydı
dc.contributor.authorGökten, Murat
dc.contributor.authorZırh, Selim
dc.contributor.authorSezer, Can
dc.contributor.authorZırh, Elham Bahador
dc.contributor.authorGökten, Dilara Bulut
dc.date.accessioned2025-04-06T12:21:55Z
dc.date.available2025-04-06T12:21:55Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractBackground: Traumatic spinal cord injury (SCI) is the most common preventable cause of morbidity. Despite rapid advances in medicine, effective pharmacological treatment against SCI has not yet been confirmed. This study aimed to investigate the possible anti-inflammatory, antiapoptotic, and neuroprotective effects of safinamide after SCI in a rat model. Methods: A total of 40 male Wistar albino rats were randomly divided into four groups. Group 1 underwent only laminectomy. Group 2 underwent SCI after laminectomy. In group 3, SCI was performed after laminectomy, and immediately afterward, intraperitoneal physiological saline solution was administered. In group 4, SCI was performed after laminectomy, and 90 mg/kg of safinamide was given intraperitoneally immediately afterward. Moderate spinal cord damage was induced at the level of thoracic vertebra nine (T9). Neuromotor function tests were performed and levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) were measured. In both serum and spinal cord tissue, immunohistochemistry and histopathology studies were also conducted. Results: TNF-α, IL-1β, and IL-6 levels were found to be significantly increased in group 2 and group 3. In group 4, these levels were statistically significantly decreased. Group 4 also exhibited significant improvement in neuromotor function tests compared to the other groups. Histopathologically, it was found that group 4 showed significantly reduced inflammation and apoptosis compared to the other groups. Conclusion: This study revealed that safinamide has neuroprotective effects against SCI due to its anti-inflammatory, antiapoptotic, and antioxidant activities. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2024. corrected publication 2024.
dc.identifier.doi10.1007/s00068-024-02513-y
dc.identifier.endpage2577
dc.identifier.issn1863-9933
dc.identifier.issue5
dc.identifier.pmid38602541
dc.identifier.scopus2-s2.0-85189968667
dc.identifier.scopusqualityQ1
dc.identifier.startpage2569
dc.identifier.urihttps://doi.org/10.1007/s00068-024-02513-y
dc.identifier.urihttps://hdl.handle.net/20.500.11776/17010
dc.identifier.volume50
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.relation.ispartofEuropean Journal of Trauma and Emergency Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250406
dc.subjectNeuroprotective
dc.subjectRat
dc.subjectSafinamide
dc.subjectTraumatic spinal cord injury
dc.titleBeyond expectations: safinamide’s unprecedented neuroprotective impact on acute spinal cord injury
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu